Phase II study of 4-demethoxydaunorubicin in advanced ovarian carcinoma Journal Article
| Authors: | Hakes, T. B.; Daghestani, A. N.; Dougherty, J. B.; Weiselberg, L.; Raymond, V. |
| Article Title: | Phase II study of 4-demethoxydaunorubicin in advanced ovarian carcinoma |
| Abstract: | 4-Demethoxydaunorubicin (4-DMDR) is an anthracycline analogue that differs from daunorubicin (DNR) by the replacement of the methoxy group in position 4 with a proton. When given iv, 4-DMDR is five times more potent than DNR against L1210 and P388 ascitic leukemia. It is also more active against Gross leukemia than either DNR or doxorubicin (DOX). Unlike DNR or DOX, 4-DMDR has clear biologic activity when administered orally. In view of these favorable characteristics, and because 4-DMDR is significantly less cardiotoxic than either DNR or DOX in mice, dogs, and rabbits, the drug was introduced into clinical trials. |
| Keywords: | adult; cancer chemotherapy; clinical article; aged; middle aged; cisplatin; doxorubicin; drug efficacy; antineoplastic agents; adenocarcinoma; ovarian neoplasms; phase 2 clinical trial; mucosa inflammation; nausea; vomiting; cyclophosphamide; vinblastine; gastrointestinal toxicity; daunorubicin; ovary carcinoma; granulosa cell tumor; idarubicin; drug therapy; adverse drug reaction; therapy; intravenous drug administration; female genital system; endocrine system; bone marrow depression; drug evaluation; intoxication; humans; human; female; priority journal; blood and hemopoietic system |
| Journal Title: | Cancer Treatment Reports |
| Volume: | 69 |
| Issue: | 5 |
| ISSN: | 0361-5960 |
| Publisher: | National Cancer Institute |
| Date Published: | 1985-05-01 |
| Start Page: | 559 |
| End Page: | 560 |
| Language: | English |
| PUBMED: | 3859369 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Export Date: 26 October 2021 -- Source: Scopus |
Citation Impact
Related MSK Work